Radiological, biochemical and hereditary evidence of two types of autosomal dominant osteopetrosis
commonly causes blindness, severe nerve damage and blood problems such as anaemia.
InterMune currently markets ACTIMMUNE(R) (Interferon gamma-1b) Injection in the United States for the treatment of chronic granulomatous disease (CGD) and severe, malignant osteopetrosis
and is in Phase III clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF) and multidrug-resistant tuberculosis (MDR TB).
By chance one of them had read about osteopetrosis
The couple have become members of the Osteopetrosis
Support Trust and are helping to fundraise for the little-known charity.
Prenatal diagnosis of malignant osteopetrosis
in Bedouin families by linkage analysis.
Type II autosomal dominant osteopetrosis
(Albers-Schonberg disease): Clinical and radiological manifestations in 42 patients.
We also wish to point out Kain suffers from osteopetrosis
and not osteoporosis as reported.
Albers-Schonberg Disease, or type II autosomal dominant osteopetrosis
(ADO2), (5) was described for the first time in 1904 by the German radiologist Heinrich Albers-Schonberg (1).
ACTIMMUNE(R) is currently marketed in the United States for CGD and severe, malignant osteopetrosis
In addition to launching ACTIMMUNE(R) for the treatment of a new disease indication, osteopetrosis
, we made significant progress towards the initiation of a Phase III pivotal trial for ACTIMMUNE(R) in the treatment of idiopathic pulmonary fibrosis (IPF).
A high dose, injectable formulation of interferon gamma has already been approved for the treatment of chronic granulomatous disease, a congenital disorder of the immune system of children and for the treatment of osteopetrosis
, a life-threatening disorder causing the overgrowth of bony structures.